Methacrylic acid, methyl ester
RTECS #
OZ5075000
CAS #
Updated
December 2018
Molecular Weight
100.13
Molecular Formula
C5H8O2
Synonyms
2-(Methoxycarbonyl)-1-propene
2-Methyl-2-propenoic acid methyl ester
2-Propenoic acid, 2-methyl-, methyl ester
Acrylic acid, 2-methyl-, methyl ester
Metakrylan metylu (Polish)
Methacrylate de methyle (French)
Methacrylsaeuremethyl ester (German)
Methyl 2-methyl-2-propenoate
Methyl alpha-methylacrylate
Methyl methacrylate
Methyl methacrylate (ACGIH:OSHA)
Methyl methacrylate monomer
Methyl methylacrylate
Methyl-2-methyl-2-propenoate
Methyl-2-methylpropenoate
Methylester kyseliny methakrylove (Czech)
Methylmethacrylaat (Dutch)
Methyl-methacrylat (German)
Metil metacrilato (Italian)
MME
NCI-C50680
Pegalan
RCRA waste number U162
2-Methyl-2-propenoic acid methyl ester
2-Propenoic acid, 2-methyl-, methyl ester
Acrylic acid, 2-methyl-, methyl ester
Metakrylan metylu (Polish)
Methacrylate de methyle (French)
Methacrylsaeuremethyl ester (German)
Methyl 2-methyl-2-propenoate
Methyl alpha-methylacrylate
Methyl methacrylate
Methyl methacrylate (ACGIH:OSHA)
Methyl methacrylate monomer
Methyl methylacrylate
Methyl-2-methyl-2-propenoate
Methyl-2-methylpropenoate
Methylester kyseliny methakrylove (Czech)
Methylmethacrylaat (Dutch)
Methyl-methacrylat (German)
Metil metacrilato (Italian)
MME
NCI-C50680
Pegalan
RCRA waste number U162
Skin and Eye Irritation and References
| Route/Organism | Dose | Effect | Reference |
|---|---|---|---|
| eye /rabbit | 150 mg | INMEAF 14,292,1945 | |
| skin /rabbit | 10 gm open irritation test | JIHTAB 23,343,1941 | |
| skin /woman | 2%/48H | CODEDG 57,21,2007 |
Mutation Data and Reference
| System Test | Route/Organism/Tissue | Dose | Reference |
|---|---|---|---|
| Cytogenetic Analysis | inhalation/rat | 4 mg/m3/16W | BZARAZ 27(6),102,1974 |
| Cytogenetic Analysis | lymphocyte/mouse | 2799 mg/L | EMMUEG 11,49,1988 |
| Cytogenetic Analysis | lymphocyte/mouse | 2202 mg/L | MUREAV 222,191,1989 |
| Cytogenetic Analysis | ovary/hamster | 1600 mg/L | NTPTR* NTP-TR-314,1986 |
| micronucleus test | lymphocyte/mouse | 2202 mg/L | MUREAV 222,191,1989 |
| mutation in mammalian somatic cells | lymphocyte/mouse | 704 mg/L | NTPTR* NTP-TR-314,1986 |
| mutation in microorganisms | lymphocyte/mouse | 500 mg/L (+enzymatic activation step) | ENMUDM 8(Suppl 6),4,1986 |
| mutation in microorganisms | /Salmonella typhimurium | 34 mmol/L (-enzymatic activation step) | JBJSA3 61A,1203,1979 |
| sister chromatid exchange | ovary/hamster | 1500 mg/L | NTPTR* NTP-TR-314,1986 |
Reproductive Effects Data and References
| Route/Organism | Dose | Effect | Reference |
|---|---|---|---|
| inhalation/woman | 10 mg/m3 (9Y pregnant) | Reproductive: Other effects on female Reproductive: Effects on embryo or fetus: Extra embryonic structures (e.g., placenta, umbilical cord) Reproductive: Effects on newborn: Delayed effects | GISAAA 62(4),19,1997 |
| inhalation/rat | 109 gm/m3/17M (6-15D pregnant) | Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus) Reproductive: Specific developmental abnormalities: Musculoskeletal system | TXAPA9 50,451,1979 |
| inhalation/rat | 109 gm/m3/54M (6-15D pregnant) | Reproductive: Effects on embryo or fetus: Fetal death Reproductive: Other developmental abnormalities | TXAPA9 50,451,1979 |
| inhalation/rat | 54 mg/m3/24H (8W prior to copulation) | Reproductive: Maternal effects: Menstrual cycle changes or disorders | GTPZAB 21(2),49,1977 |
| inhalation/rat | 4480 mg/m3/2H (6-18D pregnant) | Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants) | TOLED5 31(Suppl),80,1986 |
| inhalation/mouse | 116 ppm/6H (4-13D pregnant) | Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants) Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus) Reproductive: Specific developmental abnormalities: Musculoskeletal system | NTIS** OTS0555600 |
| inhalation/rat | 500 mg/m3 (122D prior to copulation) | Reproductive: Other developmental abnormalities | PREND* 37,51,1991 |
| inhalation/rat | 500 mg/m3 (119D prior to copulation) | Reproductive: Effects on fertility: Pre- implantation mortality (e.g., reduction in number of implants per female; total number of implants per corpora lutea) Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants) Reproductive: Other developmental abnormalities | PROEAS 37,51,1991 |
| inhalation/rat | 500 mg/m3 (98D prior to copulation/21D pregnant) | Reproductive: Other developmental abnormalities | PROEAS 37,51,1991 |
| intraperitoneal/rat | 405 mg/kg (5-15D pregnant) | Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus) Reproductive: Other developmental abnormalities | JDREAF 51,1632,1972 |
| intraperitoneal/rat | 801 mg/kg (5-15D pregnant) | Reproductive: Other developmental abnormalities | JDREAF 51,1632,1972 |
Tumorigenic Data and References
| Route/Organism | Dose | Effect | Reference |
|---|---|---|---|
| implant/rat | lowest published toxic dose: 1620 mg/kg | Tumorigenic: Equivocal tumorigenic agent by RTECS criteria Tumorigenic: Tumors at site of application | CORTBR 88,223,1972 |
Acute Toxicity Data and References
| Route/Organism | Dose | Effect | Reference |
|---|---|---|---|
| In Vitro/Human, lung | Inhibitor Concentration (50 percent kill): 176 gm/L/3H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 27,174,2013 |
| In Vitro/Human, lung | Inhibitor Concentration (50 percent kill): 63 gm/L/24H | In Vitro Toxicity Studies: Cell membrane integrity: Cytoplasmic enzymes leakage (lactate dehydrogenase, ATP enzymes etc.) | TIVIEQ 27,174,2013 |
| In Vitro/Human, lung | Inhibitor Concentration (50 percent kill): 157 gm/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 27,174,2013 |
| In Vitro/Human, lung | Inhibitor Concentration (50 percent kill): 61 gm/L/24H | In Vitro Toxicity Studies: Other assays | TIVIEQ 27,174,2013 |
| In Vitro/Human, lung tumor | Inhibitor Concentration (50 percent kill): 1.8 gm/L/24H | In Vitro Toxicity Studies: Cell membrane integrity: Cytoplasmic enzymes leakage (lactate dehydrogenase, ATP enzymes etc.) | TIVIEQ 27,174,2013 |
| In Vitro/Human, lung tumor | Inhibitor Concentration (50 percent kill): 2.7 gm/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 27,174,2013 |
| In Vitro/Human, lymphocyte | Inhibitor Concentration (30 percent kill): >200 mg/L/45H | In Vitro Toxicity Studies: Cell viability (dye exclusion): trypan blue assay etc. | TIVIEQ 29,901,2015 |
| In Vitro/Human, lymphocyte | Inhibitor Concentration (50 percent kill): 157 mg/L/45H | In Vitro Toxicity Studies: Other assays | TIVIEQ 29,901,2015 |
| In Vitro/Human, skin | Inhibitor Concentration Low: 10 µmol/L/24H | Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | TXAPA9 283,147,2015 |
| In Vitro/Human, skin | Inhibitor Concentration (20 percent kill): 400.5 mg/L/21H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 27,314,2013 |
| In Vitro/Human, skin | Inhibitor Concentration Low: 400.5 mg/L/4H | In Vitro Toxicity Studies: Other assays | TIVIEQ 27,314,2013 |
| In Vitro/Mouse, fibroblast | Inhibitor Concentration (50 percent kill): 1.7 gm/L/24H | In Vitro Toxicity Studies: Cell membrane integrity: Cytoplasmic enzymes leakage (lactate dehydrogenase, ATP enzymes etc.) | TIVIEQ 27,174,2013 |
| In Vitro/Mouse, fibroblast | Inhibitor Concentration (50 percent kill): 1.6 gm/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 27,174,2013 |
| In Vitro/mra | Inhibitor Concentration (25 percent kill): 5000 mg/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TOLED5 216,65,2013 |
| In Vitro/mra | Inhibitor Concentration Low: 50 mg/L/24H | Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | TOLED5 216,65,2013 |
| In Vitro/Rat, lung | Inhibitor Concentration (50 percent kill): >501.2 mmol/L/1H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 32,347,2016 |
| In Vitro/Rat, lung | Inhibitor Concentration (50 percent kill): >501.2 mmol/L/1H | In Vitro Toxicity Studies: Cell protein synthesis | TIVIEQ 32,347,2016 |
| In Vitro/Rat, lung | Inhibitor Concentration (50 percent kill): 123 mmol/L/1H | Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | TIVIEQ 32,347,2016 |
| inhalation/Dog | Lowest published lethal concentration: 41200 mg/m3/3H | Behavioral: Somnolence (general depressed activity) Behavioral: Ataxia Gastrointestinal: Changes in structure or function of salivary glands | INMEAF 14,292,1945 |
| inhalation/guinea pig | Lowest published lethal concentration: 19000 mg/m3/5H | Behavioral: Muscle weakness Behavioral: Coma Lung, Thorax, or Respiration: Respiratory depression | JIHTAB 23,343,1941 |
| inhalation/human | lowest published toxic concentration: 125 ppm | Behavioral: Sleep Behavioral: Excitement Behavioral: Anorexia (human) | GISAAA 19(10),25,1954 |
| inhalation/human | lowest published toxic concentration: 60 mg/m3 | Behavioral: Sleep Behavioral: Excitement Vascular: BP lowering not characterized in autonomic section | GTPZAB 1,56,1957 |
| inhalation/mammal (species unspecified) | lethal concentration (50 percent kill): 20 gm/m3 | GISAAA 51(5),61,1986 | |
| inhalation/mouse | lethal concentration (50 percent kill): 18500 mg/m3/2H | GTPZAB 20(6),5,1976 | |
| inhalation/rabbit | Lowest published lethal concentration: 17500 mg/m3/4.5H | Behavioral: Muscle weakness Behavioral: Coma Lung, Thorax, or Respiration: Respiratory depression | JIHTAB 23,343,1941 |
| inhalation/rat | lethal concentration (50 percent kill): 78000 mg/m3/4H | GTPZAB 20(6),5,1976 | |
| inhalation/rat | lowest published toxic concentration: 400 ppm/4H | Olfaction: Ulcerated nasal septum Olfaction: Other olfaction effects | TOXID9 60,150,2001 |
| intraperitoneal/guinea pig | lethal dose (50 percent kill): 1890 mg/kg | Behavioral: Somnolence (general depressed activity) | INMEAF 14,292,1945 |
| intraperitoneal/mouse | lethal dose (50 percent kill): 945 mg/kg | Behavioral: Somnolence (general depressed activity) | INMEAF 14,292,1945 |
| intraperitoneal/rat | lethal dose (50 percent kill): 1328 mg/kg | JDREAF 51,1632,1972 | |
| intravenous/Dog | lowest published lethal dose: 120 µL/kg | JPMSAE 63,376,1974 | |
| oral/Dog | lethal dose (50 percent kill): 4725 mg/kg | Behavioral: Somnolence (general depressed activity) Behavioral: Ataxia Gastrointestinal: Changes in structure or function of salivary glands | INMEAF 14,292,1945 |
| oral/guinea pig | lethal dose (50 percent kill): 5954 mg/kg | Behavioral: Somnolence (general depressed activity) Behavioral: Ataxia Gastrointestinal: Changes in structure or function of salivary glands | INMEAF 14,292,1945 |
| oral/mouse | lethal dose (50 percent kill): 3625 mg/kg | GISAAA 41(4),6,1976 | |
| oral/rabbit | lethal dose (50 percent kill): 8700 mg/kg | GISAAA 41(4),6,1976 | |
| oral/rat | lethal dose (50 percent kill): 7872 mg/kg | Behavioral: Muscle weakness Behavioral: Coma Lung, Thorax, or Respiration: Respiratory depression | JIHTAB 23,343,1941 |
| skin/rabbit | lethal dose (50 percent kill): >5 gm/kg | Skin: After systemic exposure: Dermatitis, other | NTIS** OTS0544282 |
| subcutaneous/cat | lowest published lethal dose: 7 mL/kg | Peripheral Nerve and Sensation: Spastic paralysis with/without sensory change Kidney, Ureter, and Bladder: Changes primarily in glomeruli Biochemical: Metabolism (intermediary): Porphyrin including bile pigments | NTIS** OTS0520933 |
| subcutaneous/Dog | lethal dose (50 percent kill): 4252 mg/kg | Behavioral: Somnolence (general depressed activity) | INMEAF 14,292,1945 |
| subcutaneous/guinea pig | lethal dose (50 percent kill): 5954 mg/kg | Behavioral: Somnolence (general depressed activity) | INMEAF 14,292,1945 |
| subcutaneous/mouse | lethal dose (50 percent kill): 5954 mg/kg | Behavioral: Somnolence (general depressed activity) | INMEAF 14,292,1945 |
| subcutaneous/rabbit | lowest published lethal dose: 14 mL/kg | Behavioral: Somnolence (general depressed activity) Lung, Thorax, or Respiration: Other changes Kidney, Ureter, and Bladder: Hematuria | NTIS** OTS0520933 |
| subcutaneous/rat | lethal dose (50 percent kill): 7088 mg/kg | Behavioral: Somnolence (general depressed activity) | INMEAF 14,292,1945 |
Other Multiple Dose Data and References
| Route/Organism | Dose | Effect | Reference |
|---|---|---|---|
| inhalation/cat | lowest published toxic concentration: 15 gm/m3/7H/5D- intermittent | Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field | NTIS** OTS0520933 |
| inhalation/Dog | lowest published toxic concentration: 47 gm/m3/90M/15D- intermittent | Liver: Fatty liver degeneration Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field | INMEAF 14,292,1945 |
| inhalation/guinea pig | lowest published toxic concentration: 65 gm/m3/3H/3D- intermittent | Liver: Fatty liver degeneration Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field | INMEAF 14,292,1945 |
| inhalation/hamster | lowest published toxic concentration: 400 ppm/6H/78W- intermittent | Nutritional and Gross Metabolic: Weight loss or decreased weight gain Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field | NTIS** OTS0521056 |
| inhalation/mouse | lowest published toxic concentration: 41 gm/m3/90M/15D- intermittent | Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field | INMEAF 14,292,1945 |
| inhalation/mouse | lowest published toxic concentration: 5000 ppm/6H/14W- intermittent | Olfaction: Other olfaction effects Liver: Hepatitis (hepatocellular necrosis), zonal Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field | NTPTR* NTP-TR-314,1986 |
| inhalation/mouse | lowest published toxic concentration: 500 ppm/6H/2Y- intermittent | Olfaction: Other olfaction effects Lung, Thorax, or Respiration: Fibrosis, focal (pneumoconiosis) | TXCYAC 52,237,1988 |
| inhalation/mouse | lowest published toxic concentration: 30900 mg/kg/103W- intermittent | Reproductive: Tumorigenic effects: Uterine tumors Tumorigenic: Active as anti-cancer agent | NTIS** PB87-146742/AS |
| inhalation/rabbit | lowest published toxic concentration: 15 gm/m3/7H/5D- intermittent | Kidney, Ureter, and Bladder: Other changes in urine composition Biochemical: Metabolism (intermediary): Porphyrin including bile pigments | NTIS** OTS0520933 |
| inhalation/rat | lowest published toxic concentration: 50 mg/m3/4H/30D- intermittent | Endocrine: Change in LH Endocrine: Change in gonadotropins Related to Chronic Data: Changes in ovarian weight | PREND* 37,51,1991 |
| inhalation/rat | lowest published toxic concentration: 500 mg/m3/4H/122D- intermittent | Endocrine: Other changes | PREND* 37,51,1991 |
| inhalation/rat | lowest published toxic concentration: 116 ppm/8H/26W- intermittent | Blood: Changes in serum composition (e.g. TP, bilirubin, cholesterol) Nutritional and Gross Metabolic: Changes in: P Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Transaminases | ENVRAL 11,66,1976 |
| inhalation/rat | lowest published toxic concentration: 5000 ppm/6H/14W- intermittent | Brain and Coverings: Changes in circulation Olfaction: Other olfaction effects Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field | NTPTR* NTP-TR-314,1986 |
| inhalation/rat | lowest published toxic concentration: 34500 mg/m3/16W- intermittent | Liver: Fatty liver degeneration Kidney, Ureter, and Bladder: Other changes Biochemical: Metabolism (intermediary): Amino acids (including renal excretion) | GISAAA 45(10),74,1980 |
| inhalation/rat | lowest published toxic concentration: 1 mg/m3/24H/60D- continuous | Behavioral: Muscle contraction or spasticity Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: True cholinesterase Biochemical: Metabolism (intermediary): Porphyrin including bile pigments | GISAAA 27(11),3,1962 |
| inhalation/rat | lowest published toxic concentration: 115 mg/m3/3H/17W- intermittent | Cardiac: EKG changes not diagnostic of above Blood: Other changes | GISAAA 45(1),34,1980 |
| inhalation/rat | lowest published toxic concentration: 500 ppm/6H/2Y- intermittent | Olfaction: Other olfaction effects Lung, Thorax, or Respiration: Fibrosis, focal (pneumoconiosis) | TXCYAC 52,237,1988 |
| inhalation/rat | lowest published toxic concentration: 50 mg/m3/4H/4W- intermittent | Endocrine: Change in LH Endocrine: Change in gonadotropins Related to Chronic Data: Changes in ovarian weight | PROEAS 37,51,1991 |
| inhalation/rat | lowest published toxic concentration: 50 mg/m3/4H/17W- intermittent | Brain and Coverings: Other degenerative changes | PROEAS 37,51,1991 |
| inhalation/rat | lowest published toxic concentration: 15450 mg/kg/103W- intermittent | Brain and Coverings: Tumors Tumorigenic: Active as anti-cancer agent | NTIS** PB87-146742/AS |
| intraperitoneal/mouse | lowest published toxic dose: 19665 mL/kg/15W- intermittent | Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field | JBMRBG 8,11,1974 |
| oral/Dog | lowest published toxic dose: 1825 mg/kg/2Y- continuous | Endocrine: Changes in spleen weight | TXAPA9 6,29,1964 |
| oral/rabbit | lowest published toxic dose: 97500 µg/kg/39W- intermittent | Brain and Coverings: Other degenerative changes Liver: Other changes Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Transaminases | GISAAA 41(4),6,1976 |
| oral/rat | lowest published toxic dose: 10500 mg/kg/21D- intermittent | Peripheral Nerve and Sensation: Structural change in nerve or sheath Behavioral: Somnolence (general depressed activity) Biochemical: Metabolism (intermediary): Lipids including transport | INHEAO 27,121,1989 |
| oral/rat | lowest published toxic dose: 17896 mg/kg/35W- intermittent | Gastrointestinal: Ulceration or bleeding from stomach Liver: Other changes | AMPMAR 32,653,1971 |
Reviews
| Organization | Standard | Reference |
|---|---|---|
| American Conference of Governmental Industrial Hygienists (ACGIH) | Threshold Limit Value-time-weighted average 50 ppm;short term exposure limit 100 ppm (sen) | DTLVS* TLV/BEI,2013 |
| American Conference of Governmental Industrial Hygienists (ACGIH) | Threshold Limit Value-Not classifiable as a human carcinogen | DTLVS* TLV/BEI,2013 |
| International Agency for Research on Cancer (IARC) | Cancer Review:Animal Inadequate Evidence | IMEMDT 19,187,1979 |
| International Agency for Research on Cancer (IARC) | Cancer Review:Human No Adequate Data | IMEMDT 19,187,1979 |
| International Agency for Research on Cancer (IARC) | Cancer Review:Human Inadequate Evidence | IMEMDT 60,445,1994 |
| International Agency for Research on Cancer (IARC) | Cancer Review:Animal LACK CARCINOGENICITY | IMEMDT 60,445,1994 |
| International Agency for Research on Cancer (IARC) | Cancer Review:Group 3 | IMEMDT 60,445,1994 |
| TOXICOLOGY REVIEW | EVHPAZ 11,141,1975 | |
| TOXICOLOGY REVIEW | CMTVAS 10(3),49,1973 | |
| TOXICOLOGY REVIEW | MUREAV 566,21,2004 | |
| TOXICOLOGY REVIEW | TOLED5 138,9,2003 | |
| TOXICOLOGY REVIEW | MUREAV 543,201,2003 | |
| TOXICOLOGY REVIEW | IJTOFN 24,53,2005 | |
| TOXICOLOGY REVIEW | MUREAV 584,1,2005 | |
| TOXICOLOGY REVIEW | FCTOD7 47,1287,2009 | |
| TOXICOLOGY REVIEW | FCTOD7 49,1877,2011 | |
| TOXICOLOGY REVIEW | FCTOD7 55,596,2013 | |
| TOXICOLOGY REVIEW | MUREAV 802,1,2016 | |
| TOXICOLOGY REVIEW | RTOPDW 54,294,2009 | |
| TOXICOLOGY REVIEW | RTOPDW 55,43,2009 | |
| TOXICOLOGY REVIEW | RTOPDW 56,54,2010 |
Standards and Regulations
| Organization | Standard | Reference |
|---|---|---|
| Mine Safety and Health Administration (MSHA) STANDARD-air | time-weighted average 100 ppm (410 mg/m3) | DTLVS* 3,168,1971 |
| Occupational Exposure Limit IN ARGENTINA, BULGARIA, COLOMBIA, JORDAN check ACGIH TLV; | ||
| Occupational Exposure Limit IN SINGAPORE, VIETNAM check ACGIH TLV | ||
| Occupational Exposure Limit-AUSTRALIA | time-weighted average 50 ppm (208 mg/m3), short term exposure limit 100 ppm (416 mg/m3), JUL2008 | |
| Occupational Exposure Limit-AUSTRIA | MAK-TMW 50 ppm (210 mg/m3);KZW 100 ppm (420 mg/m3), sen, 2007 | |
| Occupational Exposure Limit-BELGIUM | time-weighted average 100 ppm (416 mg/m3), MAR2002 | |
| Occupational Exposure Limit-DENMARK | time-weighted average 25 ppm (102 mg/m3), skin, MAY2011 | |
| Occupational Exposure Limit-FINLAND | time-weighted average 10 ppm (42 mg/m3), short term exposure limit 50 ppm (210 mg/m3), NOV2011 | |
| Occupational Exposure Limit-FRANCE | VME 100 ppm (410 mg/m3), VLE 200 ppm (820 mg/m3), FEB2006 | |
| Occupational Exposure Limit-GERMANY | MAK 50 ppm (210 mg/m3), skin, sen, 2011 | |
| Occupational Exposure Limit-HUNGARY | time-weighted average 210 mg/m3, short term exposure limit 210 mg/m3, Skin, SEP2000 | |
| Occupational Exposure Limit-ICELAND | time-weighted average 25 ppm (102 mg/m3), skin, sen, NOV2011 | |
| Occupational Exposure Limit-JAPAN | Occupational Exposure Limit 2 ppm, skin, MAY2012 | |
| Occupational Exposure Limit-KOREA | time-weighted average 100 ppm (410 mg/m3), 2006 | |
| Occupational Exposure Limit-MEXICO | time-weighted average 100 ppm (410 mg/m3);short term exposure limit 125 ppm (510 mg/m3), 2004 | |
| Occupational Exposure Limit-NEW ZEALAND | time-weighted average 50 ppm (208 mg/m3); short term exposure limit 100 ppm (416 mg/m3), skin, sen, JAN2002 | |
| Occupational Exposure Limit-PERU | time-weighted average 50 ppm (205 mg/m3); short term exposure limit 100 ppm (410 mg/m3), JUL2005 | |
| Occupational Exposure Limit-POLAND | MAC(time-weighted average) 50 mg/m3, MAC(short term exposure limit) 400 mg/m3, JAN1999 | |
| Occupational Exposure Limit-RUSSIA | time-weighted average 10 mg/m3, short term exposure limit 20 mg/m3, JUN2003 | |
| Occupational Exposure Limit-SWEDEN | time-weighted average 50 ppm (200 mg/m3);short term exposure limit 150 ppm (600 mg/m3), Skin, Sen, JUN2005 | |
| Occupational Exposure Limit-SWITZERLAND | MAK-week 50 ppm (210 mg/m3), KZG-week 100 ppm (420 mg/m3), sen, JAN2011 | |
| Occupational Exposure Limit-THE NETHERLANDS | MAC-TGG 40 mg/m3, 2003 | |
| Occupational Exposure Limit-THE PHILIPPINES | time-weighted average 100 ppm (410 mg/m3), JAN1993 | |
| Occupational Exposure Limit-UNITED KINGDOM | time-weighted average 50 ppm (208 mg/m3);short term exposure limit 100 ppm (416 mg/m3), OCT2007 | |
| Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (Construction) | 8H time-weighted average 100 ppm (410 mg/m3) | CFRGBR 29,1926.55,1994 |
| Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (Federal Contractors) | 8H time-weighted average 100 ppm (410 mg/m3) | CFRGBR 41,50-204.50,1994 |
| Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (General Industry) | 8H time-weighted average 100 ppm (410 mg/m3) | CFRGBR 29,1910.1000,1994 |
| Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (Shipyards) | 8H time-weighted average 100 ppm (410 mg/m3) | CFRGBR 29,1915.1000,1993 |
NIOSH Documentation and Surveillance
| Organization | Standard | Reference |
|---|---|---|
| National Institute for Occupational Safety and Health (NIOSH) Recommended Exposure Level TO METHYL METHACRYLATE-air | 10H time-weighted average 100 ppm | NIOSH* DHHS #92-100,1992 |
| National Occupational Exposure Survey 1983 | Hazard Code 47700; Number of Industries 76; Total Number of Facilities 6757; Number of Occupations 80; Total Number of Employees Exposed 170079; Total Number of Female Employees Exposed 59519 | |
| National Occupational Hazard Survey 1974 | Hazard Code 47700; Number of Industries 89; Total Number of Facilities 11522; Number of Occupations 73; Total Number of Employees Exposed 89435 |
Status in Federal Agencies
| Organization | Reference |
|---|---|
| EPA TSCA 8(a) PRELIMINARY ASSESSMENT INFORMATION, FINAL RULE | FEREAC 47,26992,82 |
| EPA TSCA Section 8(b) CHEMICAL INVENTORY | |
| EPA TSCA Section 8(d) unpublished health/safety studies | |
| EPA TSCA TEST SUBMISSION (TSCATS) DATA BASE, JANUARY 2001 | |
| NCI Carcinogenesis Studies (inhal);no evidence:mouse,rat | |
| NIOSH Analytical Method, 1994: Methyl methacrylate, 2537 | |
| On EPA IRIS database | |
| OSHA ANALYTICAL METHOD #94 |
Page last reviewed: November 16, 2018
Content
source: National Institute for Occupational Safety and Health